NOP16 and acute myeloid leukemia: Among them, only RRP9 was significantly upregulated in AML patients (Fig. 4A), whereas NOP16 and NOP56 showed no significant changes (Fig. S5A, B), and DDX21 was downregulated (Fig. S5C).